Spots Global Cancer Trial Database for recurrent osteosarcoma

Every month we try and update this database with for recurrent osteosarcoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors	NCT02867592	Adrenal Cortica... Alveolar Soft P... Central Nervous... Childhood Clear... Clear Cell Sarc... Ewing Sarcoma Hepatoblastoma Hepatocellular ... Osteosarcoma Recurrent Adren... Recurrent Alveo... Recurrent Clear... Recurrent Ewing... Recurrent Hepat... Recurrent Hepat... Recurrent Kidne... Recurrent Malig... Recurrent Osteo... Recurrent Prima... Recurrent Renal... Recurrent Rhabd... Recurrent Soft ... Recurrent Thyro... Refractory Adre... Refractory Alve... Refractory Clea... Refractory Ewin... Refractory Hepa... Refractory Hepa... Refractory Mali... Refractory Oste... Refractory Prim... Refractory Prim... Refractory Rena... Refractory Rhab... Refractory Soft... Refractory Thyr... Refractory Wilm... Renal Cell Carc... Rhabdomyosarcom... Soft Tissue Sar... Solid Neoplasm Thyroid Gland M... Wilms Tumor	Cabozantinib Cabozantinib S-... Pharmacological...	2 Years - 30 Years	National Cancer Institute (NCI)
Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)	NCT03526250	Advanced Malign... Recurrent Child... Recurrent Ewing... Recurrent Gliom... Recurrent Hepat... Recurrent Kidne... Recurrent Lange... Recurrent Malig... Recurrent Malig... Recurrent Medul... Recurrent Neuro... Recurrent Non-H... Recurrent Osteo... Recurrent Perip... Recurrent Rhabd... Recurrent Rhabd... Recurrent Soft ... Refractory Epen... Refractory Ewin... Refractory Glio... Refractory Hepa... Refractory Lang... Refractory Mali... Refractory Mali... Refractory Medu... Refractory Neur... Refractory Non-... Refractory Oste... Refractory Peri... Refractory Rhab... Refractory Rhab... Refractory Soft...	Laboratory Biom... Palbociclib Pharmacological...	12 Months - 21 Years	National Cancer Institute (NCI)
High-Dose Methotrexate in Treating Young Patients With Solid Tumors	NCT00513981	Brain and Centr... Sarcoma Unspecified Chi...	leucovorin calc... methotrexate mass spectromet... pharmacological...	- 21 Years	National Cancer Institute (NCI)
IM83 Clinical Study of CAR-T Cell Therapy in Patients With Relapsed or Refractory Osteosarcoma	NCT06412458	Refractory Oste... Recurrent Osteo...	IM83 CAR-T Cell...	16 Years -	Beijing Immunochina Medical Science & Technology Co., Ltd.
Ecteinascidin 743 in Treating Patients With Previously Treated Metastatic Osteosarcoma	NCT00005625	Sarcoma	trabectedin	12 Years -	Memorial Sloan Kettering Cancer Center
Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma	NCT02484443	Metastatic Mali... Metastatic Oste... Recurrent Osteo...	Dinutuximab Laboratory Biom... Pharmacological... Sargramostim	- 29 Years	National Cancer Institute (NCI)
Glembatumumab Vedotin in Treating Patients With Recurrent or Refractory Osteosarcoma	NCT02487979	Recurrent Osteo...	Glembatumumab V... Laboratory Biom... Pharmacological...	12 Years - 49 Years	National Cancer Institute (NCI)
Biomarkers in Predicting Response to Chemotherapy in Samples From Young Patients With Osteosarcoma	NCT01374672	Localized Osteo... Metastatic Oste... Osteoblastic Os... Recurrent Osteo...	laboratory biom...	10 Years - 20 Years	Children's Oncology Group
Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery	NCT01553539	Bone Cancer Chondrosarcoma Clear Cell Sarc... Metastatic Oste... Ovarian Sarcoma Recurrent Adult... Recurrent Osteo... Recurrent Uteri... Stage III Adult... Stage III Uteri... Stage IV Adult ... Stage IV Uterin...	therapeutic ang... laboratory biom...	18 Years -	Wake Forest University Health Sciences
Methotrexate, Trimetrexate Glucuronate, and Leucovorin in Treating Patients With Refractory or Recurrent Osteosarcoma	NCT00119301	Sarcoma	leucovorin calc... methotrexate trimetrexate gl...	1 Year - 35 Years	Memorial Sloan Kettering Cancer Center
Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation	NCT06041490	Liver Transplan... Hepatocarcinoma Recurrent Osteo... High-Risk Cance...	multi-kinase in...	18 Years - 75 Years	Peking Union Medical College Hospital
Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma	NCT04668300	Metastatic Angi... Metastatic Dedi... Metastatic Oste... Recurrent Angio... Recurrent Dedif... Recurrent Osteo... Refractory Dedi... Refractory Oste...	Durvalumab Oleclumab	12 Years -	M.D. Anderson Cancer Center
Conformal Radiation Therapy in Treating Patients With Metastatic Cancer Outside the Brain	NCT00550654	Kidney Cancer Melanoma (Skin) Metastatic Canc... Ovarian Cancer Sarcoma Unspecified Adu...	questionnaire a... 3-dimensional c... hypofractionate... image-guided ra... tomotherapy	18 Years -	National Institutes of Health Clinical Center (CC)
Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia, Osteosarcoma, or Non-Hodgkin's Lymphoma	NCT00002738	Leukemia Lymphoma Sarcoma	leucovorin calc... trimetrexate gl...	- 21 Years	Memorial Sloan Kettering Cancer Center
LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas	NCT03449108	Bone Sarcoma Dedifferentiate... Giant Cell Tumo... Malignancy in G... Malignant Solid... Ovarian Carcino... Platinum-Resist... Poorly Differen... Recurrent Osteo... Recurrent Ovari... Refractory Oste... Soft Tissue Sar... Thyroid Gland A... Thyroid Gland S... Undifferentiate... Triple Negative...	Aldesleukin Autologous Tumo... Autologous Tumo... Cyclophosphamid... Fludarabine Ipilimumab Nivolumab Quality-of-Life... Questionnaire A...	16 Years - 70 Years	M.D. Anderson Cancer Center
Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma	NCT01016015	Metastatic Oste... Recurrent Adult... Recurrent Osteo... Stage III Adult... Stage IV Adult ...	Cixutumumab Laboratory Biom... Temsirolimus	16 Years -	National Cancer Institute (NCI)
Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)	NCT03698994	Advanced Malign... Recurrent Epend... Recurrent Ewing... Recurrent Gliom... Recurrent Hepat... Recurrent Histi... Recurrent Lange... Recurrent Malig... Recurrent Malig... Recurrent Medul... Recurrent Neuro... Recurrent Non-H... Recurrent Osteo... Recurrent Perip... Recurrent Prima... Recurrent Rhabd... Recurrent Rhabd... Recurrent Soft ... Refractory Epen... Refractory Ewin... Refractory Glio... Refractory Hepa... Refractory Hist... Refractory Lang... Refractory Mali... Refractory Mali... Refractory Medu... Refractory Neur... Refractory Non-... Refractory Oste... Refractory Peri... Refractory Prim... Refractory Rhab... Refractory Rhab... Refractory Soft... Wilms Tumor	Pharmacokinetic... Ulixertinib	12 Months - 21 Years	National Cancer Institute (NCI)
Inhaled Sargramostim in Treating Patients With First Pulmonary (Lung) Recurrence of Osteosarcoma	NCT00066365	Metastatic Canc... Sarcoma	sargramostim conventional su...	- 39 Years	Children's Oncology Group
Pepinemab in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors	NCT03320330	Recurrent Malig... Recurrent Osteo... Refractory Mali... Refractory Oste...	Laboratory Biom... Pepinemab Pharmacological...	12 Months - 30 Years	Children's Oncology Group
Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia, Osteosarcoma, or Non-Hodgkin's Lymphoma	NCT00002738	Leukemia Lymphoma Sarcoma	leucovorin calc... trimetrexate gl...	- 21 Years	Memorial Sloan Kettering Cancer Center
Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation	NCT06041490	Liver Transplan... Hepatocarcinoma Recurrent Osteo... High-Risk Cance...	multi-kinase in...	18 Years - 75 Years	Peking Union Medical College Hospital
Samarium Sm 153 and Stem Cell Transplant Followed By Radiation Therapy Patients With Osteosarcoma	NCT00245011	Sarcoma	filgrastim ifosfamide peripheral bloo... Sm-EDTMP (low d... sm-EDTMP (highe...	13 Years - 50 Years	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma	NCT04751383	High Risk Neuro... Recurrent Neuro... Recurrent Osteo... Refractory Neur... Resectable Oste...	Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Computed Tomogr... Dinutuximab Magnetic Resona... Magrolimab Resection	2 Years - 35 Years	National Cancer Institute (NCI)
Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma	NCT02097238	Recurrent Osteo...	Eribulin Mesyla... Pharmacological...	12 Years - 49 Years	National Cancer Institute (NCI)
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial	NCT04284774	Malignant Solid... Recurrent Adren... Recurrent Ectom... Recurrent Epend... Recurrent Ewing... Recurrent Hepat... Recurrent Kidne... Recurrent Lange... Recurrent Malig... Recurrent Malig... Recurrent Medul... Recurrent Melan... Recurrent Neuro... Recurrent Non-H... Recurrent Osteo... Recurrent Perip... Recurrent Rhabd... Recurrent Rhabd... Recurrent Rhabd... Recurrent Soft ... Recurrent Thyro... Recurrent WHO G... Refractory Adre... Refractory Epen... Refractory Ewin... Refractory Hepa... Refractory Lang... Refractory Mali... Refractory Mali... Refractory Medu... Refractory Mela... Refractory Neur... Refractory Non-... Refractory Oste... Refractory Peri... Refractory Rhab... Refractory Rhab... Refractory Rhab... Refractory Soft... Refractory Thyr... Refractory WHO ...	Biospecimen Col... Bone Marrow Asp... Computed Tomogr... Magnetic Resona... Positron Emissi... Radionuclide Im... Tipifarnib	12 Months - 21 Years	National Cancer Institute (NCI)
Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)	NCT03213678	Advanced Malign... Ann Arbor Stage... Ann Arbor Stage... Malignant Gliom... Recurrent Epend... Recurrent Ewing... Recurrent Gliom... Recurrent Hepat... Recurrent Lange... Recurrent Malig... Recurrent Malig... Recurrent Medul... Recurrent Neuro... Recurrent Non-H... Recurrent Osteo... Recurrent Perip... Recurrent Prima... Recurrent Rhabd... Recurrent Soft ... Refractory Lang... Refractory Mali... Refractory Mali... Refractory Neur... Refractory Non-... Refractory Prim... Rhabdoid Tumor Stage III Osteo... Stage III Soft ... Stage IV Osteos... Stage IV Soft T... Stage IVA Osteo... Stage IVB Osteo... Wilms Tumor	Biospecimen Col... Computed Tomogr... FDG-Positron Em... Magnetic Resona... Samotolisib X-Ray Imaging	12 Months - 21 Years	National Cancer Institute (NCI)
Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery	NCT01553539	Bone Cancer Chondrosarcoma Clear Cell Sarc... Metastatic Oste... Ovarian Sarcoma Recurrent Adult... Recurrent Osteo... Recurrent Uteri... Stage III Adult... Stage III Uteri... Stage IV Adult ... Stage IV Uterin...	therapeutic ang... laboratory biom...	18 Years -	Wake Forest University Health Sciences
Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial	NCT04320888	Hematopoietic a... Recurrent Epend... Recurrent Ewing... Recurrent Hepat... Recurrent Histi... Recurrent Lange... Recurrent Lymph... Recurrent Malig... Recurrent Malig... Recurrent Malig... Recurrent Medul... Recurrent Neuro... Recurrent Non-H... Recurrent Osteo... Recurrent Perip... Recurrent Rhabd... Recurrent Rhabd... Recurrent Soft ... Recurrent WHO G... Refractory Epen... Refractory Ewin... Refractory Hepa... Refractory Hist... Refractory Lang... Refractory Lymp... Refractory Mali... Refractory Mali... Refractory Mali... Refractory Medu... Refractory Neur... Refractory Non-... Refractory Oste... Refractory Peri... Refractory Rhab... Refractory Rhab... Refractory Soft... Refractory WHO ... Wilms Tumor	Computed Tomogr... Magnetic Resona... Positron Emissi... Radionuclide Im... Selpercatinib X-Ray Imaging	12 Months - 21 Years	National Cancer Institute (NCI)
Cabozantinib S-malate in Treating Patients With Relapsed Osteosarcoma or Ewing Sarcoma	NCT02243605	Metastatic Ewin... Metastatic Oste... Recurrent Ewing... Recurrent Osteo... Stage III Osteo... Stage IV Osteos... Stage IVA Osteo... Stage IVB Osteo... Unresectable Ew... Unresectable Os...	Cabozantinib S-... Laboratory Biom...	12 Years -	National Cancer Institute (NCI)
Methotrexate, Trimetrexate Glucuronate, and Leucovorin in Treating Patients With Refractory or Recurrent Osteosarcoma	NCT00119301	Sarcoma	leucovorin calc... methotrexate trimetrexate gl...	1 Year - 35 Years	Memorial Sloan Kettering Cancer Center
Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)	NCT03698994	Advanced Malign... Recurrent Epend... Recurrent Ewing... Recurrent Gliom... Recurrent Hepat... Recurrent Histi... Recurrent Lange... Recurrent Malig... Recurrent Malig... Recurrent Medul... Recurrent Neuro... Recurrent Non-H... Recurrent Osteo... Recurrent Perip... Recurrent Prima... Recurrent Rhabd... Recurrent Rhabd... Recurrent Soft ... Refractory Epen... Refractory Ewin... Refractory Glio... Refractory Hepa... Refractory Hist... Refractory Lang... Refractory Mali... Refractory Mali... Refractory Medu... Refractory Neur... Refractory Non-... Refractory Oste... Refractory Peri... Refractory Prim... Refractory Rhab... Refractory Rhab... Refractory Soft... Wilms Tumor	Pharmacokinetic... Ulixertinib	12 Months - 21 Years	National Cancer Institute (NCI)
Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer	NCT01132547	Cancer	cyproheptadine ... placebo	2 Years - 21 Years	University of South Florida
High-Dose Methotrexate in Treating Young Patients With Solid Tumors	NCT00513981	Brain and Centr... Sarcoma Unspecified Chi...	leucovorin calc... methotrexate mass spectromet... pharmacological...	- 21 Years	National Cancer Institute (NCI)
Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia, Osteosarcoma, or Non-Hodgkin's Lymphoma	NCT00002738	Leukemia Lymphoma Sarcoma	leucovorin calc... trimetrexate gl...	- 21 Years	Memorial Sloan Kettering Cancer Center
IM83 Clinical Study of CAR-T Cell Therapy in Patients With Relapsed or Refractory Osteosarcoma	NCT06412458	Refractory Oste... Recurrent Osteo...	IM83 CAR-T Cell...	16 Years -	Beijing Immunochina Medical Science & Technology Co., Ltd.
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors	NCT04851119	Colorectal Carc... Endometrial Car... Melanoma Neuroblastoma Ovarian Carcino... Pancreatic Duct... Recurrent Desmo... Recurrent Ewing... Recurrent Hepat... Recurrent Hepat... Recurrent Malig... Recurrent Non-H... Recurrent Osteo... Refractory Desm... Refractory Ewin... Refractory Hepa... Refractory Hepa... Refractory Mali... Refractory Non-... Refractory Oste... Solid Pseudopap... Wilms Tumor	Biospecimen Col... Dual X-ray Abso... Tegavivint X-Ray Imaging	12 Months - 30 Years	Children's Oncology Group
Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors	NCT00620295	Breast Cancer Colorectal Canc... Head and Neck C... Kidney Cancer Lung Cancer Ovarian Cancer Pancreatic Canc... Prostate Cancer Sarcoma	bortezomib gemcitabine hyd...	70 Years -	Masonic Cancer Center, University of Minnesota
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma	NCT04870944	Diffuse Midline... Metastatic Mali... Recurrent Diffu... Recurrent Lymph... Recurrent Malig... Recurrent Osteo... Recurrent Prima... Refractory Lymp... Refractory Mali... Refractory Oste... Refractory Prim...	Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Echocardiograph... FACT Complex-ta...	12 Months - 30 Years	Children's Oncology Group
Biomarker Expression in Tissue Samples From Patients With Bone Sarcomas	NCT01807052	Localized Osteo... Metastatic Oste... Recurrent Osteo...	laboratory biom...	- 39 Years	Children's Oncology Group
Conformal Radiation Therapy in Treating Patients With Metastatic Cancer Outside the Brain	NCT00550654	Kidney Cancer Melanoma (Skin) Metastatic Canc... Ovarian Cancer Sarcoma Unspecified Adu...	questionnaire a... 3-dimensional c... hypofractionate... image-guided ra... tomotherapy	18 Years -	National Institutes of Health Clinical Center (CC)
Alanosine in Treating Patients With Cancer	NCT00062283	Lung Cancer Malignant Mesot... Pancreatic Canc... Sarcoma	L-alanosine	13 Years -	National Cancer Institute (NCI)
Registry For Children, Adolescents And Adults With Osteosarcoma And Biologically Related Bone Sarcomas	NCT05515068	Osteosarcoma Bone Tumor Bone Sarcoma High Grade Sarc... Osteoblastic Os... Chondroblastic ... Fibroblastic Os... Conventional Os... Conventional Ce... Low Grade Centr... Osseous Sarcoma Osseous Tumor Small Cell Oste... Telangiectatic ... Undifferentiate... Parosteal Osteo... Periosteal Oste... Extraskeletal O... Recurrent Osteo... High Grade Surf... Osseous Angiosa... Osseous Fibrosa... Osseous Leiomyo... Osseous Dediffe... Osseous Mesench... Clear Cell Oste...		-	Klinikum Stuttgart
Trastuzumab Deruxtecan for the Treatment of HER2+ Newly Diagnosed or Recurrent Osteosarcoma	NCT04616560	Osteosarcoma Recurrent Osteo...	Trastuzumab Der...	12 Years - 39 Years	National Cancer Institute (NCI)
Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors	NCT00620295	Breast Cancer Colorectal Canc... Head and Neck C... Kidney Cancer Lung Cancer Ovarian Cancer Pancreatic Canc... Prostate Cancer Sarcoma	bortezomib gemcitabine hyd...	70 Years -	Masonic Cancer Center, University of Minnesota
Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma	NCT02097238	Recurrent Osteo...	Eribulin Mesyla... Pharmacological...	12 Years - 49 Years	National Cancer Institute (NCI)
Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma	NCT02502786	Recurrent Osteo...	humanized anti-... GM-CSF	13 Months - 40 Years	Memorial Sloan Kettering Cancer Center
Ecteinascidin 743 in Treating Patients With Previously Treated Metastatic Osteosarcoma	NCT00005625	Sarcoma	trabectedin	12 Years -	Memorial Sloan Kettering Cancer Center
Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma	NCT02502786	Recurrent Osteo...	humanized anti-... GM-CSF	13 Months - 40 Years	Memorial Sloan Kettering Cancer Center
Study of Blood Samples From Patients With Osteosarcoma	NCT00954473	Localized Osteo... Metastatic Oste... Recurrent Osteo...	laboratory biom...	-	Children's Oncology Group
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)	NCT03155620	Advanced Malign... Ann Arbor Stage... Ann Arbor Stage... Histiocytic Sar... Juvenile Xantho... Langerhans Cell... Malignant Gliom... Recurrent Child... Recurrent Epend... Recurrent Ewing... Recurrent Gliom... Recurrent Hepat... Recurrent Lange... Recurrent Malig... Recurrent Malig... Recurrent Medul... Recurrent Neuro... Recurrent Non-H... Recurrent Osteo... Recurrent Perip... Recurrent Prima... Recurrent Rhabd... Recurrent Soft ... Refractory Ewin... Refractory Glio... Refractory Hepa... Refractory Lang... Refractory Mali... Refractory Mali... Refractory Medu... Refractory Neur... Refractory Non-... Refractory Oste... Refractory Peri... Refractory Prim... Refractory Rhab... Refractory Rhab... Rhabdoid Tumor Stage III Osteo... Stage III Soft ... Stage IV Osteos... Stage IV Soft T... Stage IVA Osteo... Stage IVB Osteo... Wilms Tumor	Biopsy Biospecimen Col... Bone Marrow Asp... Bone Scan Computed Tomogr... Ensartinib Erdafitinib Laboratory Biom... Larotrectinib S... Magnetic Resona... Mutation Carrie... Olaparib Palbociclib Pharmacological... Positron Emissi... Radionuclide Im... Samotolisib Selpercatinib Selumetinib Sul... Tazemetostat Tipifarnib Ulixertinib Vemurafenib X-Ray Imaging	12 Months - 21 Years	National Cancer Institute (NCI)
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma	NCT04870944	Diffuse Midline... Metastatic Mali... Recurrent Diffu... Recurrent Lymph... Recurrent Malig... Recurrent Osteo... Recurrent Prima... Refractory Lymp... Refractory Mali... Refractory Oste... Refractory Prim...	Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Echocardiograph... FACT Complex-ta...	12 Months - 30 Years	Children's Oncology Group
Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma	NCT04901702	Recurrent Solid... Recurrent Ewing... Recurrent Hepat... Recurrent Malig... Recurrent Malig... Recurrent Neuro... Recurrent Osteo... Recurrent Perip... Recurrent Rhabd... Recurrent Rhabd... Recurrent Soft ... Recurrent Wilms... Refractory Ewin... Refractory Hepa... Refractory Mali... Refractory Mali... Refractory Neur... Refractory Oste... Refractory Peri... Refractory Rhab... Refractory Rhab... Refractory Soft...	Onivyde Talazoparib Temozolomide	12 Months - 30 Years	St. Jude Children's Research Hospital
Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, The GD2-CAR PERSIST Trial	NCT04539366	Recurrent Neuro... Recurrent Osteo... Refractory Neur... Refractory Oste...	Biopsy Biospecimen Col... Cyclophosphamid... Echocardiograph... Fludarabine Pho... GD2-CAR-express... Imaging Techniq... Magnetic Resona... Multigated Acqu...	- 40 Years	National Cancer Institute (NCI)
Monoclonal Antibody A1G4 Plus BCG in Treating Patients With Cancer	NCT00003023	Neuroblastoma Sarcoma	BCG vaccine monoclonal anti...	-	Memorial Sloan Kettering Cancer Center
Methotrexate, Trimetrexate Glucuronate, and Leucovorin in Treating Patients With Refractory or Recurrent Osteosarcoma	NCT00119301	Sarcoma	leucovorin calc... methotrexate trimetrexate gl...	1 Year - 35 Years	Memorial Sloan Kettering Cancer Center
Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)	NCT03526250	Advanced Malign... Recurrent Child... Recurrent Ewing... Recurrent Gliom... Recurrent Hepat... Recurrent Kidne... Recurrent Lange... Recurrent Malig... Recurrent Malig... Recurrent Medul... Recurrent Neuro... Recurrent Non-H... Recurrent Osteo... Recurrent Perip... Recurrent Rhabd... Recurrent Rhabd... Recurrent Soft ... Refractory Epen... Refractory Ewin... Refractory Glio... Refractory Hepa... Refractory Lang... Refractory Mali... Refractory Mali... Refractory Medu... Refractory Neur... Refractory Non-... Refractory Oste... Refractory Peri... Refractory Rhab... Refractory Rhab... Refractory Soft...	Laboratory Biom... Palbociclib Pharmacological...	12 Months - 21 Years	National Cancer Institute (NCI)

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: